These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 27329383)
1. Role of Side Effects, Physician Involvement, and Patient Perception in Non-Adherence with Oral Bisphosphonates. Goldshtein I; Rouach V; Shamir-Stein N; Yu J; Chodick G Adv Ther; 2016 Aug; 33(8):1374-84. PubMed ID: 27329383 [TBL] [Abstract][Full Text] [Related]
2. Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims. Copher R; Buzinec P; Zarotsky V; Kazis L; Iqbal SU; Macarios D Curr Med Res Opin; 2010 Apr; 26(4):777-85. PubMed ID: 20095797 [TBL] [Abstract][Full Text] [Related]
3. Adherence to anti-osteoporotic therapies: role and determinants of "spot therapy". Tafaro L; Nati G; Leoni E; Baldini R; Cattaruzza MS; Mei M; Falaschi P Osteoporos Int; 2013 Aug; 24(8):2319-23. PubMed ID: 23404614 [TBL] [Abstract][Full Text] [Related]
4. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Curtis JR; Westfall AO; Allison JJ; Freeman A; Saag KG Osteoporos Int; 2006; 17(8):1268-74. PubMed ID: 16724286 [TBL] [Abstract][Full Text] [Related]
5. Natural history, reasons for, and impact of low/non-adherence to medications for osteoporosis in a cohort of community-dwelling older women already established on medication: a 2-year follow-up study. Clark EM; Gould VC; Tobias JH; Horne R Osteoporos Int; 2016 Feb; 27(2):579-90. PubMed ID: 26286625 [TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA). Landfeldt E; Lang A; Robbins S; Ström O Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544 [TBL] [Abstract][Full Text] [Related]
7. Patients' reasons for adhering to long-term alendronate therapy. Pepe J; Cipriani C; Cecchetti V; Ferrara C; Della Grotta G; Danese V; Colangelo L; Minisola S Osteoporos Int; 2019 Aug; 30(8):1627-1634. PubMed ID: 31089764 [TBL] [Abstract][Full Text] [Related]
8. Physicians' perspectives on the treatment of osteoporosis patients with bisphosphonates. Gu T; Eisenberg Lawrence DF; Stephenson JJ; Yu J Clin Interv Aging; 2016; 11():1-8. PubMed ID: 26929609 [TBL] [Abstract][Full Text] [Related]
9. Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis. Park JH; Park EK; Koo DW; Lee S; Lee SH; Kim GT; Lee SG BMC Musculoskelet Disord; 2017 Apr; 18(1):152. PubMed ID: 28399834 [TBL] [Abstract][Full Text] [Related]
10. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Devold HM; Furu K; Skurtveit S; Tverdal A; Falch JA; Sogaard AJ Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):297-304. PubMed ID: 22237942 [TBL] [Abstract][Full Text] [Related]
11. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study. Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038 [TBL] [Abstract][Full Text] [Related]
12. Adherence to alendronate in male veterans. Hansen KE; Swenson ED; Baltz B; Schuna AA; Jones AN; Elliott ME Osteoporos Int; 2008 Mar; 19(3):349-56. PubMed ID: 17898921 [TBL] [Abstract][Full Text] [Related]
13. The effect of mandatory generic substitution on the safety of alendronate and patients' adherence. Lai PS; Chua SS; Chong YH; Chan SP Curr Med Res Opin; 2012 Aug; 28(8):1347-55. PubMed ID: 22746354 [TBL] [Abstract][Full Text] [Related]
14. Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines. Cheng TT; Yu SF; Hsu CY; Chen SH; Su BY; Yang TS Clin Ther; 2013 Jul; 35(7):1005-15. PubMed ID: 23831360 [TBL] [Abstract][Full Text] [Related]
15. Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment. Modi A; Tang J; Sen S; Díez-Pérez A Curr Med Res Opin; 2015 Apr; 31(4):767-77. PubMed ID: 25708648 [TBL] [Abstract][Full Text] [Related]
16. Predictors and Outcomes Associated With Adherence to Weekly Alendronate in US Military Veterans: Clinical Research Study. Bou Malham S; Bowe B; Sen SK; Zhang RM; Sterkel B; Dunn JP J Prim Care Community Health; 2019; 10():2150132719884300. PubMed ID: 31779523 [No Abstract] [Full Text] [Related]
17. Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study. Gonnelli S; Caffarelli C; Letizia Mauro G; Di Munno O; Malavolta N; Migliaccio S; Nuti R Aging Clin Exp Res; 2019 Nov; 31(11):1541-1547. PubMed ID: 31030419 [TBL] [Abstract][Full Text] [Related]
18. Bone Mass Outcomes in Patients With Osteoporosis Treated With Risedronate After Alendronate Failure: a 12-Month Follow-Up Study. Mendonça LT; Pinheiro MM; Szejnfeld VL; Castro CH J Clin Densitom; 2017; 20(1):44-49. PubMed ID: 27616291 [TBL] [Abstract][Full Text] [Related]
19. Early (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: A Population-Based Cohort Study. Carbonell-Abella C; Pages-Castella A; Javaid MK; Nogues X; Farmer AJ; Cooper C; Diez-Perez A; Prieto-Alhambra D Calcif Tissue Int; 2015 Dec; 97(6):535-41. PubMed ID: 26202819 [TBL] [Abstract][Full Text] [Related]
20. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday. Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]